Abstract | BACKGROUND AIMS: METHODS: We characterized the immunophenotype of HSC subsets isolated from the peripheral blood of eight patients with multiple myeloma (MM) before and after treatment with plerixafor. All patients were supposed to collect stem cells prior to high-dose chemotherapy and consecutive autologous stem cell transplantation, and therefore received front-line mobilization with 4 days of G-CSF followed by a single dose of plerixafor. Samples of peripheral blood were analyzed comparatively by flow cytometry directly before and 12 h after administration of plerixafor. RESULTS: The number of aldehyde dehydrogenase (ALDH)(bright) and CD34(+) cells was significantly higher after plerixafor treatment (1.2-5.0 and 1.5-6.0 times; both P < 0.01) and an enrichment of the very primitive CD34(+) CD38(-) and ALDH(bright) CD34(+) CD38(-) HSC subsets was detectable. Additionally, two distinct ALDH(+) subsets could be clearly distinguished. The small ALDH(high) subset showed a higher number of CD34(+) CD38(-) cells in contrast to the total ALDH(bright) subpopulation and probably represented a very primitive subpopulation of HSC. CONCLUSIONS: A combined staining of ALDH, CD34 and CD38 might represent a powerful tool for the identification of a very rare and primitive hematopoietic stem cell subset. The addition of plerixafor mobilized not only more CD34(+) cells but was also able to increase the proportion of more primitive stem cell subsets.
|
Authors | Isabel Taubert, Rainer Saffrich, Abraham Zepeda-Moreno, Isabelle Hellwig, Volker Eckstein, Thomas Bruckner, Anthony D Ho, Patrick Wuchter |
Journal | Cytotherapy
(Cytotherapy)
Vol. 13
Issue 4
Pg. 459-66
(Apr 2011)
ISSN: 1477-2566 [Electronic] England |
PMID | 21077729
(Publication Type: Journal Article)
|
Chemical References |
- Benzylamines
- Cyclams
- Heterocyclic Compounds
- Receptors, CXCR4
- plerixafor
|
Topics |
- Aged
- Benzylamines
- Cells, Cultured
- Cyclams
- Female
- Hematopoietic Stem Cell Mobilization
(methods)
- Hematopoietic Stem Cells
(cytology, drug effects, metabolism)
- Heterocyclic Compounds
(therapeutic use)
- Humans
- Male
- Middle Aged
- Multiple Myeloma
(metabolism, pathology)
- Polymerase Chain Reaction
- Receptors, CXCR4
(antagonists & inhibitors)
|